logo
Plus   Neg
Share
Email

Frontier IP: Exscientia To Get Up To €240 Mln In AI-based Drug Deal With Bayer

Frontier IP Group Plc announced Friday that Artificial Intelligence- driven drug discovery company Exscientia has entered into a collaboration with Bayer AG (BAYZF.PK,BAYRY.PK,BYR.L) focused on cardiovascular disease and oncology.

Under the deal terms, Exscientia will initially work on three projects with targets agreed between both parties.

Exscientia may be eligible to receive up to 240 million euros including upfront and research payments, and for meeting near term and clinical milestones. The company may also receive sales royalties.

Joerg Moeller, Member of the Executive Committee of Bayer AG's Pharmaceuticals Division and Head of Research and Development said, "We are driving forward digital transformation in R&D as we believe that digital technologies such as AI can simplify and speed up the discovery and development of new drugs for patients. The collaboration with Exscientia is expected to help us to achieve project milestones earlier and at the same time accelerate timelines by enabling more precise identification of suitable drug targets and lead structures."

Exscientia's other partnerships include collaborations with Celgene, GSK, Roche, Sanofi, GT Apeiron, Rallybio and Evotec.

Frontier IP currently holds a 3.25 percent stake in the company.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Safavieh LLC recalled about 760 units of Aura and Silas 3-Drawer Chests for possible serious tip-over and entrapment hazards that can result in death or injuries to children, the U.S. Consumer Product Safety Commission said in a statement. The company said the chests are unstable if they are not anchored to the wall. Shares of Standard Chartered Plc were losing around 4 percent in London trading after the bank warned on fiscal 2020 income growth mainly due to coronavirus impact. This was despite reporting a profit before tax in its fourth quarter, compared to last year's loss. For 2020, the company now expects income growth to be below its medium-term target range of 5 percent to 7 percent. A 2018 fatal crash involving a Tesla Inc. vehicle was likely caused by the car's autopilot system as well as distracted driving, according to a report by the National Transportation Safety Board or NTSB. The driver of the Tesla's Model X electric-powered sport utility vehicle, Walter Huang, was killed when it collided with a damaged crash attenuator on March 23, 2018 in Mountain View, California.
Follow RTT
>